The effects of carboplatin and etoposide on advanced small cell lung cancer and serum tumor markers in correlation with long-term survival rate.
Objective of the present study was to analyze the efficacy of recombinant human endo-statin combined with carboplatin and etoposide regimen (CE regimen) in treatment of patients with advanced small cell lung cancer and its effects on serum tumor markers of CY211, CEA and CA199. A total of 72 patients at Zhejiang Taizhou Hospital, Taizhou, Zhejiang, China were randomly divided into control group and observation group (36 cases each). The control group was treated with carboplatin and etoposide while the observation group additionally received recombinant human endo-statin. Clinical remission rate and adverse reaction rate were compared between the two groups. Before treatment, there was no significant difference (P>0.05) between the two groups in serum tumor markers of CY211, CEA and CA199 while after treatment, the CY211, CEA and CA199 levels of the observation group were significantly lower than those of the control group and no significant difference was found between the two groups in the incidence of side effects as well as in the 3 and 5 year-survival rate (X2=1.125, 1.248, P>0.05). Recombinant human endo-statin combined with carboplatin and etoposide was more effective in treating advanced small cell lung cancer as it managed to reduce the level of serum tumor markers of CY211, CEA and CA199 with less side effects and high tolerance in patients, thus worthy of popularization and application in clinical trials.